Physician profile
Ryan Goldstein
NPI 1447647649
$1,783.27
in general payments reported to CMS, 2019-2025
16 companies · $98.66 in 2025
The $98.66 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $128 · 2021: $159 · 2022: $239 · 2023: $551 · 2024: $240 · 2025: $98.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.11 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.15 | 2019-2025 | |
| Celgene Corporation | $345.44 | 2022-2024 | Zeposia |
| Genzyme Corporation | $174.84 | 2023-2025 | |
| Boston Scientific Corporation | $126.32 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $116.84 | 2019-2021 | |
| Gilead Sciences, INC. | $104.14 | 2020 | |
| Janssen Scientific Affairs, LLC | $94.34 | 2023 | Tremfya, Remicade, Stelara |
| Aries Pharmaceuticals, INC. | $90.29 | 2019 | |
| Pfizer INC. | $69.70 | 2023-2025 | |
| Erbe USA INC | $54.93 | 2021 | |
| Janssen Biotech, INC. | $48.01 | 2022-2023 | Stelara, Simponi, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.97 | 2022 | |
| Ambu INC. | $36.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.08 | 2023-2025 | Gattex |
| Celltrion USA INC. | $17.67 | 2025 | Vegzelma |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.